NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.9460 +0.04 (+4.42 %)
(As of 01/18/2019 03:17 PM ET)
Previous Close$0.9050
Today's Range$0.90 - $0.9502
52-Week Range$0.47 - $3.30
Volume103,517 shs
Average Volume435,606 shs
Market Capitalization$53.40 million
P/E Ratio-1.05
Dividend YieldN/A
Beta0.18
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share

Profitability

Net Income$-54,810,000.00

Miscellaneous

Employees20
Market Cap$53.40 million
OptionableNot Optionable

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) issued its earnings results on Wednesday, November, 7th. The biotechnology company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.30. View Bellerophon Therapeutics' Earnings History.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Bellerophon Therapeutics.

What price target have analysts set for BLPH?

1 analysts have issued 12 month price targets for Bellerophon Therapeutics' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 216.5% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics.

What is the consensus analysts' recommendation for Bellerophon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics.

What are Wall Street analysts saying about Bellerophon Therapeutics stock?

Here are some recent quotes from research analysts about Bellerophon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (1/1/2019)
  • 2. HC Wainwright analysts commented, "Our new price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc." (8/9/2018)

Has Bellerophon Therapeutics been receiving favorable news coverage?

Media headlines about BLPH stock have been trending neutral on Friday, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are some of Bellerophon Therapeutics' key competitors?

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the folowing people:
  • Mr. Fabian Tenenbaum, CEO & Director (Age 45)
  • Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 64)
  • Mr. Assaf Korner, CFO & Sec. (Age 41)
  • Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 47)
  • Mr. Hunter Gillies, Acting Chief Medical Officer

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.06%). View Institutional Ownership Trends for Bellerophon Therapeutics.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Bellerophon Therapeutics.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $0.9480.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $53.40 million. The biotechnology company earns $-54,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is http://www.bellerophon.com.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]


MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel